Atlas Trials

Abrogation of Chronic Monoclonal Antibody Treatment-induced T-cell Exhaustion With DURVALUMAB in Advanced HER-2 Negative Breast Cancer

Clinical trial NCT02802098 · COMPLETED

Trial details

NCT number
NCT02802098
Sponsor
Centro Nacional de Investigaciones Oncologicas CARLOS III
Status
COMPLETED
Phase
Early Phase 1
Study type
INTERVENTIONAL
Metastatic Breast CancerBevacizumab-alone Maintenance Treatment Progression
Start date
2016-05-01
Primary completion
2019-06-01
Enrollment
25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.